Having trouble accessing articles? Reset your cache.

Northera droxidopa: Preliminary Phase III data

Top-line data from the modified intent-to-treat (mITT) population (n=160) of the double-blind, U.S. and Canadian Phase III Study 301 trial showed that Northera met the primary endpoint of significantly reducing mean composite OHQ scores from randomization to day 7 vs. placebo (1.83 vs. 0.93 points, p=0.003). The 11-point OHQ

Read the full 498 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers